Holen Sie sich die Stockscreener-App
0.4958
0.00%
0.00
Schlusskurs vom Vortag:
$0.4958
Offen:
$0.4794
24-Stunden-Volumen:
152.48K
Relative Volume:
0.52
Marktkapitalisierung:
$3.51M
Einnahmen:
$72,100
Nettoeinkommen (Verlust:
$-3.60M
KGV:
-0.4166
EPS:
-1.19
Netto-Cashflow:
$-3.37M
1W Leistung:
+8.02%
1M Leistung:
-33.89%
6M Leistung:
-48.83%
1J Leistung:
-77.96%
1-Tages-Spanne:
$0.4605
$0.49
1-Wochen-Bereich:
$0.43
$0.496
52-Wochen-Spanne:
$0.4101
$4.50
Silo Pharma Inc Stock (SILO) Company Profile
Firmenname
Silo Pharma Inc
Sektor
Branche
Telefon
(718) 400-9031
Adresse
677 N. WASHINGTON BLVD, SARASOTA
Vergleichen Sie SILO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.39 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.43 | 128.76M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1578 | 339.56M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.31 | 634.81M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.8999 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Aktie (SILO) Neueste Nachrichten
Silo Pharma's (NASDAQ:SILO) Groundbreaking Therapies Could Change The Treatment Landscape For PTSD, Fibromyalgia, MS & Alzheimer’s - simplywall.st
Silo Pharma advances PTSD treatment with new drug-device study By Investing.com - Investing.com South Africa
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 - GlobeNewswire
Silo Pharma stock plunges to 52-week low of $0.47 By Investing.com - Investing.com Canada
Silo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drug - Seeking Alpha
SiloPharma (SILO) Advances SPC-15 with New Drug-Device Study Agreement | SILO Stock News - GuruFocus
Silo Pharma Collaborates With Resyca for Drug-Device Study of PTSD Drug SPC-15 - marketscreener.com
Silo Pharma advances PTSD treatment with new drug-device study - Investing.com Australia
Breakthrough PTSD Treatment: Silo Pharma's Brain-Targeting Drug Delivery System Heads to FDA - Stock Titan
Silo Pharma Announces Closing of $2 Million Public Offering - GlobeNewswire
Silo Pharma Completes Public Offering, Raises $1.56 Million - TipRanks
Silo Pharma, Inc. Completes Public Offering Raising Approximately $2 Million - Nasdaq
Silo Pharma Announces Closing Of $2 Million Public Offering - marketscreener.com
SEC Form 424B4 filed by Silo Pharma Inc. - Quantisnow
Silo Pharma sets public offering at $0.60 per share and warrant - Investing.com Nigeria
SiloPharma (SILO) Sets $2 Million Public Offering with Warrants - GuruFocus
Silo Pharma Announces Pricing of $2 Million Public Offering - The Manila Times
Silo Pharma, Inc. Prices Public Offering of 3,333,338 Shares with Associated Warrants - Nasdaq
Silo Pharma Announces $2M Offering with 5-Year Warrants: Complete Details of Latest Financing Round - Stock Titan
Silo Pharma advances in PTSD nasal therapy trials By Investing.com - Investing.com Canada
Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment - Asianet Newsable
Silo Pharma (SILO) Partners with Veloxity Labs for Key Drug Stud - GuruFocus
Silo Pharma advances PTSD treatment study with Veloxity Labs By Investing.com - Investing.com Canada
Silo Pharma (SILO) Partners with Veloxity Labs for Key Drug Study | SILO Stock News - GuruFocus
Silo Pharma advances PTSD treatment study with Veloxity Labs - Investing.com Australia
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15 - The Manila Times
Breakthrough Intranasal PTSD Drug Heads to FDA: Silo Pharma Partners With Veloxity for Critical IND Studies - Stock Titan
Silo Pharma (SILO) Advances PTSD Treatment with New Study Agreem - GuruFocus
Silo Pharma advances in PTSD nasal therapy trials - Investing.com
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories - The Manila Times
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human - GlobeNewswire
Columbia-Licensed PTSD Drug Nears Human Trials: Silo Pharma's Novel Intranasal Treatment Hits Key Milestone - Stock Titan
Upcoming Events - FinancialContent
SILO Stock Price and Chart — NASDAQ:SILO - TradingView
Silo Pharma, Inc. (NASDAQ:SILO) Shares Sold by Renaissance Technologies LLC - Defense World
Contrasting Silo Pharma (SILO) and Its Competitors - Defense World
Silo Pharma's SP-26 Implant Achieves All Endpoints In Preclinical Fibromyalgia Study - Nasdaq
EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models - AOL.com
Silo Pharma stock hits 52-week low at $0.76 amid market challenges - Investing.com Australia
SILO Pharma Achieves Milestone with Promising Preclinical Results for SP-26 | SILO Stock News - GuruFocus
Silo Pharma reports positive preclinical results for SP-26 - Investing.com
Silo Pharma Announces Positive Preclinical Results for SP-26, a Novel Extended-Release Ketamine Implant for Fibromyalgia - Nasdaq
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia Study - marketscreener.com
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study - GlobeNewswire
Revolutionary Ketamine Implant Could Replace Opioids for Fibromyalgia Treatment, Study Shows - Stock Titan
A Guide To The Risks Of Investing In SILO Pharma Inc (SILO) - knoxdaily.com
The Significance of Moving Averages in SILO Pharma Inc Inc. (SILO) Price Performance - investchronicle.com
Finanzdaten der Silo Pharma Inc-Aktie (SILO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Silo Pharma Inc-Aktie (SILO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | CEO and President |
Dec 13 '24 |
Buy |
0.84 |
2,500 |
2,097 |
187,932 |
| Weisblum Eric | CEO and President |
Nov 20 '24 |
Buy |
0.95 |
2,500 |
2,375 |
182,932 |
| Weisblum Eric | CEO and President |
Nov 22 '24 |
Buy |
0.90 |
2,500 |
2,250 |
185,432 |
| Weisblum Eric | CEO and President |
Jun 12 '24 |
Buy |
1.11 |
4,438 |
4,926 |
180,432 |
| Weisblum Eric | CEO and President |
Jun 11 '24 |
Buy |
1.08 |
562 |
607 |
175,994 |
0.87%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):